NCT06272227View on ClinicalTrials.gov

Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

February 13, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2025

Conditions
Sarcopenia
Interventions
DRUG

alfacalcidol

Subjects assigned to arm 1 take two doses of alfacalcidol once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).

DRUG

placebo

Subjects assigned to arm 2 take two doses of placebo once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).

DRUG

Denosumab

denosumab

Trial Locations (1)

03722

Division of Endocrinology, Department of internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT06272227 - Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients | Biotech Hunter | Biotech Hunter